CAJ | 학술논문

目的：比较Xelox方案与Sox方案用于胃癌新辅助化疗的临床疗效，为胃癌患者探寻更多临床受益的治疗方法。方法随机选择兰州大学第一医院肿瘤外科收治的胃癌患者86例，根据其接受的化疗方案分为两组：以Xelox方案作为新辅助化疗的患者40例，以Sox方案作为新辅助化疗的患者46例。进行3周期的新辅助化疗后，观察和比较两组患者的近期疗效、肿瘤分期、胃癌根治性手术切除率，并对其预后进行随访观察。结果40例Xelox方案新辅助化疗的胃癌患者中，RR为12例（30.0％）；进行根治性胃癌切除术25例（62.5％），未切除15例（37.5）；术后Ⅰ期5例（12.5％）、Ⅱ期3例（7.5％）、Ⅲ期12例（30.0％）、Ⅳ期20例（50.0％）；总生存期为6~23个月，中位生存期为18个月，中位肿瘤进展时间为15个月。46例Sox方案新辅助化疗的胃癌患者中，RR为27例（59.0％）；进行根治性胃癌切除术38例（82.6％），未切除8例（17.4％）；术后Ⅰ期17例（37.0％）、Ⅱ期11例（24.0％）、Ⅲ期5例（11.0％）、Ⅳ期13例（28.0％）；生存期为8~24个月，中位生存期为23个月，中位肿瘤进展时间为20个月。结论与Xelox方案相比，Sox方案用于胃癌的新辅助化疗可更加显著地提高近期疗效，改善患者预后，患者临床获益更佳，可优先用于胃癌的治疗。
목적：비교Xelox방안여Sox방안용우위암신보조화료적림상료효，위위암환자탐심경다림상수익적치료방법。방법수궤선택란주대학제일의원종류외과수치적위암환자86례，근거기접수적화료방안분위량조：이Xelox방안작위신보조화료적환자40례，이Sox방안작위신보조화료적환자46례。진행3주기적신보조화료후，관찰화비교량조환자적근기료효、종류분기、위암근치성수술절제솔，병대기예후진행수방관찰。결과40례Xelox방안신보조화료적위암환자중，RR위12례（30.0％）；진행근치성위암절제술25례（62.5％），미절제15례（37.5）；술후Ⅰ기5례（12.5％）、Ⅱ기3례（7.5％）、Ⅲ기12례（30.0％）、Ⅳ기20례（50.0％）；총생존기위6~23개월，중위생존기위18개월，중위종류진전시간위15개월。46례Sox방안신보조화료적위암환자중，RR위27례（59.0％）；진행근치성위암절제술38례（82.6％），미절제8례（17.4％）；술후Ⅰ기17례（37.0％）、Ⅱ기11례（24.0％）、Ⅲ기5례（11.0％）、Ⅳ기13례（28.0％）；생존기위8~24개월，중위생존기위23개월，중위종류진전시간위20개월。결론여Xelox방안상비，Sox방안용우위암적신보조화료가경가현저지제고근기료효，개선환자예후，환자림상획익경가，가우선용우위암적치료。
Objective To compare the efficacy of Xelox and Sox neoadjuvant chemotherapies in the treatment of gastric cancer in order to explore a therapy with better clinical outcomes for patients. Methods A total of 86 gastric cancer cases in the Department of Oncological Surgery in First Hospital of Lanzhou University were randomly selected and divided into two groups according to different chemotherapies. And after being treated with 3 periods of neoadjuvant chemotherapies, the Xelox and Sox groups were observed and compared in terms of recent efficacy, tumor stages and radical gastrectomy rates. Prognosis follow-ups were also carried out for efficacy comparison. Results Among the 40 cases of Xelox neoadjuvant chemotherapy, there were 12 cases (30.0%) of RR, 25 cases (62.5%) of radical gastrectomy and 15 cases (37.5%) of non-radical gastrectomy;5 cases (12.5%) were in postoperative phaseⅠ, 3 cases (7.5%) in phaseⅡ,12 cases (30.0%) in phaseⅢ, and 20 cases (50.0%) in phaseⅣ;the overall survival time for the 40 cases was 6-23 months and median survival time was 18 months;time to tumor progression was from 1 to 23 months, with a median value of 15 months. Among the 46 cases of Sox neoadjuvant chemotherapy, there were 27 cases (59.0%) of RR, 38 cases (82.6%) of radical gastrectomy and 8 cases (17.4%) of non-radical gastrectomy;17 cases (37%) were in postoperative phaseⅠ,11 cases (24%) in phaseⅡ, 5 cases (11.0%) in phaseⅢ, and 13 cases (28.0%) in phaseⅣ;the overall survival time for the 46 cases was 8-24 months and median survival time 23 months;time to tumor progression was from 5 to 24 months, with a median value of 20 months. Conclusions Sox neoadjuvant chemotherapy in the treatment of gastric cancer is significantly better than xelox in terms of short-term effect, prognosis and clinical benefits, thus it is preferable for clinical application.